Research Reports | Market Assessment
August 2021

EGFR – Epidemiology – Mature Markets

UNDERSTAND THE TOTAL MARKET SIZE AND TREATMENT OPPORTUNITIES FOR BIOMARKERS

The development of biomarker-driven therapies continues to be a major trend in oncology. As biomarkers are often clinically relevant in more than one indication, the concept of sizing eligible patient populations is evolving. With DRG Biomarker Epidemiology data and insights, the entire biomarker-defined population can be sized in minutes.

EGFR KRAS BRCA ALK
Breast cancer x x x
Renal cell carinoma x
Ovarian cancer x
Prostate cancer x
Pancreatic cancer x x
Colorectal cancer x x x
Non-small-cell lung cancer x x x
Head and neck cancer x
Thyroid carcinoma x
Small-cell lung cancer x
Rare tumors x x
Source: Clarivate

FIRST-LINE DRUG-TREATABLE EGFR POPULATIONS

Breast cancer

Non-small-cell lung cancer

Small-cell lung cancer

Squamous cell carcinoma of the head and neck

Colorectal cancer

EPIDEMIOLOGY IS THE FOUNDATION OF MARKET FORECASTING AT ALL PHASES OF PRODUCT DEVELOPMENT AND STRATEGY

You need biomarker epidemiology data that you can trust in order to:

  • Complete biomarker-driven market-sizing assessments based on patient population sizes and patient flows.
  • Build the foundation of a market forecast for strategic planning for biomarker-targeting for new and existing assets.
  • Understand how the patient populations for certain biomarkers will evolve over time.
  • Answer any question you may have about specific subpopulations, biomarkers, and the impact of new studies.

Table of contents

  • EGFR - Epidemiology - Mature Markets
    • Introduction
      • Key Findings
        • Key Updates
      • Diagnosed Incidence of EGFR-Mutated Cancers per 100,000 People of All Ages in 2021 and 2031
      • Patient-Flow Diagram of EGFR-Mutated Cancers in the Major Mature Pharmaceutical Markets in 2021
      • Analysis of the Diagnosed Incidence of EGFR-Mutated Cancers in 2021 by Cancer Site
    • Epidemiology Data
    • Methods
      • Diagnosed EGFR-Mutated Incident Cases
      • Diagnosed EGFR-Mutated NSCLC Incident Cases
      • Diagnosed EGFR-Mutated SCLC Incident Cases
      • Diagnosed EGFR-Mutated SCCHN Incident Cases
      • Diagnosed EGFR-Mutated Breast Cancer Incident Cases
      • Diagnosed EGFR-Mutated Colorectal Cancer Incident Cases
      • Diagnosed EGFR-Mutated Glioblastoma Incident Cases
      • Diagnosed EGFR-Mutated First-Line Drug-Treatable Population
      • Diagnosed EGFR-Mutated NSCLC First-Line Drug-Treatable Population
      • Diagnosed EGFR-Mutated SCLC First-Line Drug-Treatable Population
      • Diagnosed EGFR-Mutated SCCHN First-Line Drug-Treatable Population
      • Diagnosed EGFR-Mutated Breast Cancer First-Line Drug-Treatable Population
      • Diagnosed EGFR-Mutated Colorectal Cancer First-Line Drug-Treatable Population
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Diagnosed Incident Cases
        • Studies Excluded in the Analysis of Diagnosed Incident Cases
      • Risk/Protective Factors
        • Bibliography
        • Abbreviations
        • Glossary
    Mudasir Khan, M.P.H.
    Mudasir Khan, M.P.H.

    Mudasir Khan, M.P.H., is a senior epidemiologist at Clarivate. His areas of expertise are oncology and psychiatry diseases. He holds a master’s degree in public health from the Tata Institute of Social Sciences in Mumbai.

    Login to access report
    Back to all Market Assessment reports
    Login to access report

    launch Related Market Assessment Reports